Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok, thanks Vance.
Hi Vance, are you sure?
I just read a PDF on their website that basically said the want an r/s.
They want to increase the authorized shares.
They want to give the BOD a raise.
I quickly skimmed the article, but those were the sad highlights.
Unfortunately, I can't find the PDF again, but you can probably find it.
I'm not lying and I'm sure there will be more discussion about it.
My experience has been, that reverse splits always pass.
I think I should sell quickly and keep my profit.
Maybe buy back in slowly, after the r/s.
I would rather they announce a partner, no r/s and no BOD raise, for a good increase in share price.
Is there an upcoming reverse split vote in June?
Previously, it Was OxiGene, then it was that Mateon scam and now it's the Oncotelic scam.
Jerseyboy, I actually think you have some good points. I had to average down, because I was already underwater and will hold until bankruptcy or a break even.
This pig needs to get going!
Ok, those are some good thoughts and let's hope there are some good catalysts soon, such as;
A clear win of the lawsuit against Clarus.
A partnership for the sales and marketing of Tlando, three times per day pill.
A good Nash phase II trial result.
Approval of Tlando once per day pill.
A good preterm phase I trial.
When will the reverse shell merger occur?
I'm not doubting you, but isn't there a milestone payment that could be good for the share price?
Well ya, if that's your entry price it sounds good. Some have averaged down. It's a risk either way. I am way under water now on ACAD, so much so, that I'm not selling and have averaged down, still worried as hell, but I am hopeful as well. Obviously, I don't like my investment being tied up for long term and being dead money. You are smarter than me! I should have averaged down last year when it dropped to $17, based on CNN's bashing.
Are you into crypto at all?
Ok, well let's hope there is some positive news. Did you see the recent Barrons article about the FDA? Fewer mergers, price fixing, more rejections, CRLs and delays...
The FDA sucks.
When will approval come?
Will this diluted pig ever rise?
Q2 2021 earnings report May 5th 2021.
Baker Brothers Info:
Look at the 1yr chart of all their holdings.
https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
I still hold ACAD and increased my position @ 23 and will increase even down. As a result, my average PPS went lower. Obviously, I'm taking a big chance here and of course I want the DRP approval ASAP. The FDA really messed us up and it doesn't look good.
LOL, ok.
When does Tlando tentative FDA approval become full approval?
Do we have to wait until the Clarus exclusivity expires?
When is the court case of Lipocine vs Clarus?
The recent Lipocine conference really bombed the share price, by waiting to market TLando in 2022 and by dealing the fatty liver biopsy results to later in 2021.
Hmmm...who's buying around $11k of OVIT shares?
The drop in share price to below 1.62 is unfortunate. Let's how what it closes at. Hopefully it won't go down any further.
I've learned to interpret CEO speak:
I will not do a dilutive offering= I will do a dilutive offering, the very next day.
No reverse split= There will be an r/s.
You get the point, CEO's say one thing and then usually do the exact opposite.
The new admin is deflating the stock market.
OVIT=LOL
AAPL = LOL
LOL, I knew it would go down after good earnings, but since I was not 100% sure, I bought a bunch before earnings and now have lost money, but will continue to hold...
Well, the stock price is sure down now. Ya, hopefully just a bump in the road.
What a joke!
Uh Oh...Oppsie, ACAD being sued, ACAD is now F'd with a capital F.
Shuman Glenn
1:31 PM ET 1/11/21 | BusinessWire
DENVER--(BUSINESS WIRE)--January 11, 2021--
Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of Acadia Pharmaceuticals, Inc. ("Acadia" or the "Company") (NYSE: ACAD). Acadia is a biopharmaceutical company focusing on the development and commercialization of medicines to address central nervous system disorders. The Company's lead drug, NUPLAZID, was approved in 2016 by the U.S. Food and Drug Administration ("FDA") for treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
The Firm's investigation relates to allegations in a securities fraud class action lawsuit against Acadia and certain of its senior officers in the U.S. District Court for the Southern District of California. The lawsuit alleges that the defendants failed to publicly disclose material facts, including: (i) adverse events, safety concerns, and mounting reports of deaths related to NUPLAZID post-commercialization, which raised the risk that the FDA would reconsider its approval of NUPLAZID and/or that industry watchdogs would warn against prescribing NUPLAZID; (ii) that Acadia undertook a campaign to pay off physicians to prescribe NUPLAZID; and (iii) that Acadia's improper business practices exposed the Company to potential regulatory scrutiny. In a June 1, 2020 ruling denying in part the motion to dismiss the lawsuit, the federal judge determined that it had been sufficiently alleged that the defendants did not properly disclose the high mortality rate during testing for NUPLAZID or the payments of kickbacks to doctors who prescribed NUPLAZID.
On April 9, 2018, following a CNN report about mounting deaths associated with NUPLAZID, Acadia's stock price fell by over 23% to close at $16.50 per share. After CNN subsequently reported on April 25, 2018 that the FDA was re-examining the safety of NUPLAZID, Acadia's stock price fell again, by nearly 22% to close at $15.20 per share.
If you currently own Acadia common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip Shuman toll free at (866) 569-4531 or email Mr. Shuman at kip@shumanlawfirm.com.
Shuman Glenn & Stecker represents investors throughout the nation, concentrating its practice in stockholder litigation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005918/en/
CONTACT: SHUMAN GLENN & STECKER
Kip B. Shuman, Esq.
100 Pine Street, Suite 1250
San Francisco, CA 94111
Tel: 866.569.4531
Fax: 303.536.7849
Email: kip@shumanlawfirm.com
Web: www.shumanlawfirm.com
SOURCE: Shuman Glenn & Stecker
Copyright Business Wire 2021
> Dow Jones Newswires
January 11, 2021 13:31 ET (18:31 GMT)
Stop talking about my ex-girlfriend! :)
Ok, that might not be a bad idea, interesting logic.
Good job!
Ya, smart to buy a lot under $1, before the 16/1 reverse split.
It's back to life.
I wonder if there will be a reverse shell merger into a new company.
I'm thinking to bring it down to about $1.90 and maybe a even a bit more, just depends on how bored or angry I become within the next couple of weeks...
My average PPS is $1.82 and I'm expecting it to go down to $.05 for the win!
Ooopsie... @ 1.32 now.
Exactly and the ultimate winning could take longer than we'd like, but let's hope for some good events soon!
In my opinion, Lipocine will win the exclusivity/patent rights, against Clarus and will win the appeals.
I say this because Lipocine already won all of their past court cases.
Unfortunately, fighting in the courts costs money and takes time.
If Lipocine wins, they could force Clarus to remove the drug from market and have all profits handed over to Lipocine.
On the other hand, Lipocine could allow the Clarus drug to remain on the market and in turn, work out a deal, where Clarus pays Lipocine a chunk of the profits.
Yes, I think eventually we'll make a profit with this investment.
Hopefully, there won't be a drastic, secondary offering, which causes massive dilution, for the sake of generating funding capital to market Tlando.
Hopefully, there won't be any toxic financing, for the sake of funding capital to market Tlando.
Hopefully, there won't be a drastic reverse split, for the sake of funding capital to market Tlando.
Hopefully, we'll get a good marketing/sales pharma partner.
Better yet, hopefully there will be a big pharma buy out, after Tlando is approved, after good Nash phase II results are released in January.
Hopefully, a bigger pharma will have no issue fighting in court and will do the buy out before the court cases are settled.
Otherwise, Lipocine may have to wait until the court cases are settled and won by Lipocine, before any big pharma offers a buy out.
It can be problematic for investors, when a development biotech pharma tries to make the move into a marketing/selling pharma...
It would at least be nice, to soon have Tlando FDA approved, even if it's approved with Clarus still having exclusivity rights until March 2022.
This tentative approval of Tlando is another garbage delay...
I think Lipocine has a good chance of winning their patent dispute against Clarus in court.
However, I know litigation is delayed, due to Covid being used as an excuse.
I also know, that if Lipocine wins in court, that Clarus will appeal many times and the FDA will drag their feet on giving Tlando full approval, with the exclusivity rights being removed from Clarus and those rights being given over to their rightful owner, Tlando.
In my opinion, Clarus should have never received FDA approval.
Hopefully, the phase II NASH results will be excellent and will be announced in January.
It would be even better if the NASH results were so good, that a phase III is not required and the drug can be brought to market for the treatment of NASH much sooner.